Validation of Microcapillary Flow Cytometry for Community-Based CD4+ T Lymphocyte Enumeration in Remote Burkina Faso by Renault, Cybèle A et al.
  The Open AIDS Journal, 2010, 4, 171-175 171 
 
  1874-6136/10  2010 Bentham Open 
Open Access 
Validation of Microcapillary Flow Cytometry for Community-Based CD4+ 
T Lymphocyte Enumeration in Remote Burkina Faso 
Cybèle A. Renault
*,1,2, Arouna Traore
3, Rhoderick N. Machekano
2,4 and Dennis M. Israelski
1,2,3,5 
1Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of 
Medicine, Stanford, California, USA 
2San Mateo/San Francisco Peninsula AIDS Research Center, San Mateo, California, USA 
3AIDS Empowerment and Treatment International (AIDSETI), Burkina Faso 
4Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA 
5Pangaea Global AIDS Foundation, San Francisco, California, USA 
Abstract: Background: CD4+ T lymphocyte enumeration plays a critical role in the initiation and monitoring of HIV-
infected patients on antiretroviral therapy. There is an urgent need for low-cost CD4+ enumeration technologies, 
particularly for use in dry, dusty climates characteristic of many small cities in Sub-Saharan Africa. 
Design: Cross-sectional study 
Methods: Blood samples from 98 HIV-infected patients followed in a community HIV clinic in Ouahigouya, Burkina 
Faso were obtained for routine CD4+ T lymphocyte count monitoring. The blood samples were divided into two aliquots, 
on which parallel CD4+ measurements were performed using microcapillary (Guava EasyCD4) and dedicated (Becton 
Dickinson FACSCount) CD4+ enumeration systems. Spearman rank correlation coefficient was calculated, and the 
sensitivity, specificity and positive predictive value (PPV) for EasyCD4 <200 cells/L were determined compared to the 
reference standard FACSCount CD4 <200 cells/L. 
Results: Mean CD4 counts for the EasyCD4 and FACSCount were 313.75 cells/L and 303.47 cells/L, respectively. The 
Spearman rank correlation coefficient was 0.92 (p<0.001). Median values using EasyCD4 were higher than those with the 
FACSCount (p=0.004). For a CD4<350 cells/uL, sensitivity of the EasyCD4 was 93.9% (95%CI 85.2-98.3%), specificity 
was 90.6% (95% CI 75.0-98.0%), and PPV was 95.4% (95%CI 87.1-99.0%). 
Conclusion: Use of the EasyCD4 system was feasible and highly accurate in the harsh conditions of this remote city in 
Sub-Saharan Africa, demonstrating acceptable sensitivity and specificity compared to a standard operating system. 
Microcapillary flow cytometry offers a cost-effective alternative for community-based, point-of-care CD4+ testing and 
could play a substantial role in scaling up HIV care in remote, resource-limited settings. 
Keywords: Low-cost CD4, CD4+ count, EasyCD4 assay, Guava Technologies, Inc., microcapillary flow cytometry, resource-
limited setting. 
INTRODUCTION 
  The roll out of antiretroviral therapy (ART) in 
developing countries has led to a focus on the creation of 
sustainable healthcare systems through improved medical 
infrastructure. In this regard, there has been increasing 
recognition of the importance of community-based care and 
treatment as a means to increase access to ART for people 
living with HIV/AIDS in severely constrained settings. 
  In this era of increased affordability and availability of 
ART, there is a critical need for low cost, high throughput, 
point-of-care monitoring of patients on antiretroviral 
therapy. When  evaluating the  cost-effectiveness  of  various  
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antiretroviral treatment and monitoring strategies (e.g. using 
CD4+ T lymphocyte enumeration, total lymphocyte count or 
HIV plasma viral load), patient monitoring using CD4+ T 
lymphocyte enumeration has been found to be the most cost-
effective strategy in resource-limited settings [1]. In this 
regard, the WHO recommends that the absolute number of 
CD4+ T lymphocytes be used as a guide to initiate ART [2], 
to initiate prophylaxis against opportunistic infections, and to 
discontinue these prophylactic medications [3]. Importantly, 
as HIV viral load assays are not widely available in the 
developing world, it is the absolute number of CD4+ cells 
that is frequently used to assess an individual’s response to 
ART [2]. In order to improve access to HIV/AIDS care and 
treatment in resource-poor countries, there is an urgent need 
for better technologies to measure the absolute number of 
CD4+ T lymphocytes. 
  Flow cytometry is the gold standard method used for 
CD4+ T lymphocyte enumeration. This technology measures 172    The Open AIDS Journal, 2010, Volume 4  Renault et al. 
the intensity of fluorescence as cells labeled with fluorescent 
antibodies pass through a laser beam. Conventional flow 
cytometry is open platform (i.e., not dedicated), meaning that 
reagents from various suppliers may be used and that the 
technology can potentially be used to perform assays other 
than CD4+ cell enumeration. Other advantages include high 
throughput and that some conventional systems do not 
require red blood cell lysis, which reduces both time and 
cost. The major disadvantages of the conventional systems 
are the need for a separate hematology analyzer in the dual 
platform systems, the complexity of the equipment (often 
requiring intensive training for several months), as well as 
the cost of the machines themselves [4]. Alternatively, 
dedicated flow cytometers (e.g., FACSCount; Becton 
Dickinson Immunocytometry, San Jose, California) are used 
for the single purpose of CD4+ T lymphocyte enumeration. 
Advantages of the dedicated systems are a lower cost of the 
machines, lack of a need for a separate hematology analyzer 
and a decreased potential for human error given the minimal 
number of steps requiring operator intervention. The 
disadvantages of this technology include a restriction on 
reagents to only those produced by the manufacturer and that 
the machines cannot be used to perform types of assays 
beyond the absolute CD4+ cell count [4]. 
  Microcapillary flow cytometry (e.g., EasyCD4; Guava 
Technologies, Hayward, California) uses a unique technique 
compared to conventional or dedicated flow cytometry. One 
important difference is that microcapillary flow cytometry 
does not require the use of sheath fluid to move cells through 
the laser beam; instead, cells pass single-file through a 
microcapillary filament. The lack of sheath fluid not only 
reduces cost but it also substantially reduces the amount of 
bio-hazardous waste generated, which is an important 
consideration in developing countries. The machine is also 
compact in size and therefore it potentially could be 
transported to rural clinic sites. Other advantages of 
microcapillary flow cytometry include the use of a low blood 
volume per sample, relatively easy-to-learn technology with 
minimal training required, low inter-laboratory variability 
presumably due to simplistic design
1 and the potential to 
perform different types of assays (i.e., in addition to CD4+ 
cell counts). The reagents are also less expensive, and the 
Guava business model allows the use of reagents produced 
by a variety of manufacturers. Lastly, the Guava EasyCD4 
also requires minimal maintenance, as the only components 
handled by laboratory personnel are the power switch, the 
sample loader and the waste vial [4]. Probably the most 
important advantage of microcapillary flow cytometry in 
developing countries is its overall low cost compared to 
conventional or dedicated flow cytometric systems [5]. 
  The Guava EasyCD4 has been evaluated in comparison 
to standard flow cytometry, specifically the BD FACSCount, 
for CD4+ T cell enumeration in HIV-infected persons in 
large urban settings in Uganda, India and Thailand. 
                                                 
1 Josefowicz SZ, Louzao R, Lam L, et al. Five-site evaluation of the Guava 
EasyCD4 assay for the enumeration of human CD4+ T cells [Abstract U-
138]. Presented at: 12
th Conference on Retroviruses and Opportunistic 
Infections; 2005; Boston. 
Correlation between the two systems was found to be 0.96 in 
Kampala, Uganda [6], 0.994 in Vellore, India [6], and 0.97 
in Bangkok, Thailand [7]. In Chennai, India, Balakrishnan, 
et al. used both systems to test 110 samples from HIV-
infected persons and found that the EasyCD4 assay had a 
sensitivity of 95% and a specificity of 100% for the 
identification of CD4+ T cell counts <200 cells/L [8].
 The 
EasyCD4 has also been compared to conventional flow 
cytometry systems, with correlations of 0.938 in comparison 
with the FACSORT in India [9] and 0.97 in comparison with 
the FACSCalibur/TruCOUNT method in Thailand [7]. In the 
United States, the EasyCD4 had comparable CD4+ T 
lymphocyte count estimates when compared to standard flow 
cytometry [5]. Notably, all of the above-mentioned 
validation studies were performed in relatively developed 
urban medical centers. 
  The objective of this study was to compare the 
performance of the Guava EasyCD4 to the Becton Dickinson 
FACSCount for community-based CD4+ T lymphocyte 
monitoring of HIV-infected patients in Burkina Faso. 
Burkina Faso is a country of over 14 million people with an 
adult HIV prevalence of 1.6% in 2007 [10]. UNAIDS reports 
that, at the end of 2007, 130,000 Burkinabé were living with 
HIV, and 61,000 of those infected were women aged 15 
years or older [10]. The country is located within the Sahel, 
the horizontal strip of Africa laying between the Sahara 
Desert in the north and the more fertile regions in the south. 
Its tropical climate has two distinct seasons: a wet season 
from May to September and a prolonged dry season that is 
marked by the harmattan, the hot, dusty wind from the 
Sahara. This study was performed during the dry season in 
the northern city of Ouahigouya, a relatively small city of 
approximately 65,000 inhabitants. In addition to comparing 
the performance of the Guava EasyCD4 to the FACSCount, 
a second objective of the study was to assess the feasibility 
of using microcapillary flow cytometry in a relatively 
undeveloped city that has a dry, dusty climate representative 
of many small cities in Sub-Saharan Africa. Similar to many 
remote laboratories in Sub-Saharan Africa, the community 
laboratory where our study was performed is unlike the 
laboratories in the large cities and academic medical centers 
where the EasyCD4 system has been evaluated in prior 
studies. Specifically, the windows in the Ouahigouya 
laboratory are not enclosed with glass; instead, metal 
shutters are the only barrier separating the laboratory from 
the outside air, and the shutters do not effectively prevent 
entry of external dust into the laboratory. Secondly, there is 
no climate control, and the laboratory is ventilated only by 
ceiling and floor fans. Lastly, although the laboratory is 
powered by electricity, thereby allowing use of medical 
equipment and refrigeration of the system reagents, the 
frequent power outages are problematic as there is no back-
up generator available for use. 
METHODS 
  Consecutive whole blood samples from 98 HIV-infected 
patients followed in a community HIV clinic in Ouahigouya 
were obtained for routine CD4+ T lymphocyte count 
monitoring. The community clinic, Appui Moral, Material et EasyCD4 for CD4+ Enumeration in Burkina Faso  The Open AIDS Journal, 2010, Volume 4    173 
Intellectuel à l’Enfant (AMMIE), is one of the six AIDS 
Empowerment and Treatment International (AIDSETI) 
associations in Burkina Faso. AIDSETI is a network of 
community-based clinics that has been funded by the World 
Bank Treatment Acceleration Program (TAP) [11]. The 
unique model of AIDSETI has been described previously 
[12]. HIV was diagnosed using the Bioline HIV 1-2 assay 
(Standard Diagnostics, Inc.). Patients gave informed consent 
to receive medical care at AMMIE, which included 
intermittent monitoring of CD4+ cell counts. Laboratory 
results were unlinked from patient identifiers before analysis. 
The study protocol was approved by the Institutional Review 
Board at Stanford University School of Medicine. 
  Blood samples were obtained from January to March 
2006. Each blood sample was divided into two aliquots, on 
which parallel CD4+ count measurement was performed 
using the EasyCD4 and the FACSCount systems. One 
technician performed testing on the EasyCD4, and two 
technicians performed testing on the FACSCount. The 
technicians were blinded to the test results on the other 
system. Testing was performed using the EasyCD4 and the 
FACSCount as directed by the respective manufacturer’s 
instructions [13, 14]. Reagents used were from the same lot 
for all tests performed on the EasyCD4. All of the samples 
were processed by both systems within 24 hours of the time 
that the blood was obtained. 
  The mean CD4+ cell counts as estimated by the 
EasyCD4 and by the FACSCount were determined. The 
Spearman rank correlation coefficient (r) was calculated, and 
the agreement between the EasyCD4 and the FACSCount 
was evaluated by Bland-Altman analysis [15]. The Wilcoxon 
Sign test was used to assess the differences in the median 
CD4+ cell counts as determined by the two systems. All 
statistical tests were performed using SPSS statistical 
software (SPSS, Inc., Chicago, Illinois, USA). 
  The samples were divided into three groups for further 
analysis: samples with FACSCount CD4+ count <200 
cells/L, FACSCount CD4+ count 200-350 cells/L and 
FACSCount CD4+ count >350 cells/L. The mean and 
median CD4+ cell count estimations as determined by the 
EasyCD4 were calculated for each of the three groups, as 
were individual Spearman rank correlation coefficients. The 
sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) for EasyCD4 <350 cells/uL 
were determined compared to the standard FACSCount CD4 
<350 cells/uL. The CD4 cell count of 350 cells/uL was 
chosen as the breakpoint for data analysis given its clinical 
relevance, as WHO recommends initiating ART when the 
CD4+ T lymphocyte count reaches this level [2]. Sensitivity 
and specificity were also calculated for correct identification 
of cell counts between 200 and 350 cells/uL, to assess the 
characteristics of the EasyCD4 system when counting cells 
in patients with critically low CD4+ cell numbers. 
RESULTS 
  Of the 98 subjects, 23.5% were men and 76.5% were 
women. The mean age of the study participants was 36.7 
years. The mean age of the male subjects was 41.6 years 
(range 16-70 years) and the mean age of the female subjects 
was 35.2 years (range 8-64 years). All of the subjects were 
infected with HIV-1; none were infected with HIV-2. 29.6% 
of the subjects were receiving ART at the time that the blood 
samples were obtained. 
  The mean CD4+ T lymphocyte count for the EasyCD4 
and FACSCount was 313.75 cells/L (S.D.=196) and 303.47 
cells/L (S.D.=229), respectively. Fig. (1) depicts the 
correlation plot of CD4+ cell counts using the two systems, 
with a calculated Spearman rank correlation coefficient (r) of 
0.92 (p<0.001). Fig. (2) displays the Bland-Altman analysis, 
which illustrates that the CD4+ counts calculated by the two 
systems were the most similar and had the least variability in 
the lower CD4+ count ranges, specifically in the range of 
CD4+ <350 cells/L. The differences in the CD4+ counts as 
measured by the two systems increased as the absolute 
CD4+ count increased, especially for CD4+ counts above 
350 cells/L. 
 
Fig. (1). Correlation Analysis of the EasyCD4 assay and 
FACSCount for cell counts (cells/L), divided into CD4+ T 
lymphocyte count by FACSCount <200 cells/L (red diamonds), 
200-350 cells/L (blue circles), and >350 cells/L (black squares). 
Spearman rank correlation coefficient = 0.92 (P<0.001). The solid 
line represents the regression line. Mean CD4 counts for the 
EasyCD4 and FACSCount systems were 313.75 cells/L and 
303.47 cells/L, respectively. 
  The CD4+ T lymphocyte count estimates by the 
EasyCD4 were frequently higher than those obtained with 
the FACSCount (p=0.006). Specifically, 62 EasyCD4 
measurements were higher than the FACSCount, 35 
EasyCD4 estimates were lower than the FACSCount, and 1 
EasyCD4 result was identical to that of the FACSCount. The 
EasyCD4 measurements were generally higher than the 
FACSCount measurements for CD4+ counts <200 cells/L 
and 200-350 cells/L (mean differences of +45.5 and +25.1 
cells/L, respectively), and the EasyCD4 measurements 
were lower than the FACSCount measurements for CD4+ 
count >350 cells/L (mean difference of –45.3 cells/L). 
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  The EasyCD4 had a sensitivity of 93.9% (95%CI 85.2-
98.3%) and specificity of 90.6% (95%CI 75.0-98.0%) to 
identify CD4+ T lymphocytes <350 cells/uL when compared 
to the FACSCount. The PPV for the Easy CD4 in this cell 
range was 95.4% (95%CI 87.1-99.0%) and NPV was 87.9% 
(95%CI 71.8-96.6%).   The sensitivity and specificity for 
correct identification of CD4+ cells within the 200-350 
cells/uL range were 74.1% (95%CI 53.7-88.9%) and 81.7% 
(95%CI 70.7-89.9%), respectively. 
 
Fig. (2). Bland-Altman Plot (n=98, HIV-infected individual whole 
blood samples) to establish agreement between the EasyCD4 assay 
and FACSCount for CD4+ T lymphocyte enumeration. CD4+ T 
lymphocyte count by FACSCount is divided into <200 cells/L 
(red diamonds), 200-350 cells/L (blue circles), and >350 cells/L 
(black squares). The solid horizontal line represents the mean 
difference between the two systems. 
  A total of 39 samples had a CD4+ count <200 cells/L as 
measured by the FACSCount; the EasyCD4 mean for this group 
was 157 cells/L (S.D.=81), the EasyCD4 median was 155 
cells/L (range 31-445) and the Spearman correlation 
coefficient was 0.823. For the 27 samples that had a CD4+ 
count 200-350 cells/L as measured by the FACSCount, the 
EasyCD4 mean was 283 cells/L (S.D.=74), the EasyCD4 
median was 271 cells/L (range 144-454) and the Spearman 
correlation coefficient was 0.771. A total of 32 samples had a 
CD4+ count >350 cells/L as measured by the FACSCount; for 
these samples, the EasyCD4 mean was 538 cells/L 
(S.D.=169), the EasyCD4 median was 537 cells/L (range 220-
1050) and the Spearman correlation coefficient was 0.709. 
DISCUSSION 
  The aim of this study was to demonstrate the feasibility of 
using the Guava EasyCD4 system in a small, remote city in 
Sub-Saharan Africa as well as to compare its performance to a 
widely used technology, the Becton Dickinson FACSCount. 
These results indicate that the use of microcapillary-based 
technology is feasible for community-based HIV/AIDS 
healthcare in this small city in Sub-Saharan Africa, and 
specifically using a laboratory that lacks a glass window barrier 
to the external dust, climate control, and a stable source of 
electricity. The results are encouraging, as there was excellent 
correlation between the two systems for CD4+ T lymphocyte 
enumeration in this relatively remote setting in Burkina Faso. 
Specifically, there was a correlation of 92% between the 
EasyCD4 and the FACSCount by Spearman rank statistics, 
which was statistically significant (p<0.001). Based on these 
results, it is apparent that the EasyCD4 is a cost-effective 
alternative for community-based, point-of-care CD4+ testing, 
and that it could play a substantial role in scaling up HIV care in 
remote, resource-limited settings. 
  As is illustrated in the two figures, the correlation between 
the two systems was highest in the CD4+ T lymphocyte range 
<350 cells/uL. Notably, because the WHO HIV treatment 
guidelines recommend that ART be initiated when the CD4+ 
cell count reaches 350 cells/uL [2], a high correlation between 
the two systems is most critical at this range of CD4+ cells. The 
performance of the EasyCD4 was more variable as the CD4+ 
cell count increased >350 cells/L, which is consistent with 
several other studies evaluating the performance of the 
EasyCD4 assay [5, 7, 8]. 
  Using the Guava EasyCD4 system, the CD4+ T 
lymphocyte counts were slightly higher compared to the 
FACSCount for CD4+ counts <350 cells/uL, but were 
generally lower than the FACSCount for CD4+ counts >350 
cells/uL. The observation that the EasyCD4 system may give 
higher cell count estimates than standard flow cytometry has 
been reported in prior studies [5-8], and clinicians should be 
aware of the tendency of the EasyCD4 to produce higher 
CD4+ cell count estimates in some cell count ranges. This 
finding could have clinical implications: if the EasyCD4 cell 
counts <350 cells/uL are indeed an overestimation of the 
actual CD4+ cell count, an overestimation could potentially 
result in an erroneous delay in the initiation of ART. 
  Importantly, this study has several limitations. First, in order 
to validate a technology for use in developing countries, it is 
important to assess the reproducibility of the results after 
waiting for a period of time after specimen collection. This is 
especially important in resource-limited settings where there is 
frequently a delay in the time to testing from the time that the 
blood samples are obtained. Secondly, we did not evaluate for 
potential operator bias; ideally, we would have studied the 
variation in test results for each blood sample when several 
different laboratory personnel operated the machine. A third 
limitation is that we did not perform the validation in HIV-
negative healthy controls; therefore, it is unclear if HIV-infected 
status has an impact on the accuracy or correlation of the two 
technologies. Similarly, as no HIV-2 infected subjects were 
included in this study, it is also unclear if the type of HIV has an 
impact on CD4+ T lymphocyte enumeration. It may also have 
been useful to assess the correlation between the two machines 
for CD8+ T lymphocyte counts in addition to CD4+ T 
lymphocyte counts. 
  There are several notable challenges of using low-cost 
technologies for CD4+ T lymphocyte enumeration in devel-
oping countries. Issues pertaining to quality assurance and 
quality control are in the forefront, as it is critical to ensure that 
samples are processed correctly and to ensure that test results 
are comparable between individual laboratories. Secondly, 
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access to routine technological maintenance can be difficult, 
especially in remote parts of developing countries. Excessive 
heat and dust are frequently problematic, particularly in Sub-
Saharan countries with dry and sandy conditions; the dust may 
interfere especially with technical components such as lasers. 
Unreliable sources of electricity are a common problem, not 
only creating difficulties with using the machines themselves 
but also for maintaining the required refrigeration of the 
reagents. The reagents may have a relatively short half-life and 
therefore require frequent replenishment of supplies, which can 
be challenging in remote areas. 
  Low-cost diagnostics are intrinsic to effective HIV/AIDS 
health service delivery. These results demonstrating the 
feasibility of microcapillary flow cytometry are promising, but 
novel technologies are urgently needed. Developments in low-
cost diagnostic test methods for the monitoring of HIV-infected 
individuals are underway. Transfix is a blood stabilizing 
compound that permits accurate CD4+ T lymphocyte 
enumeration more than 48 hours after blood has been obtained, 
and it has been studied for use with the Guava system
2. There is 
also a recently developed microchip that, using the principle of 
microfluidics, appears promising as a simple method for CD4+ 
T lymphocyte enumeration [16]. Further research into patterns 
of utilization and cost-benefit analyses need to be performed in 
order to define effective systems for monitoring patients with 
HIV/AIDS. 
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